Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Abstract Background The identification of biomarkers to select patients with metastatic renal cell carcinoma (mRCC) most likely to respond to combination immunotherapy (IO) is needed. We sought to investigate an association of the baseline neutrophil-to-eosinophil ratio (NER) with outcomes to nivolu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Matthew D. Tucker, Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman, Emily N. Kinsey, Kristin K. Ancell, Kathryn E. Beckermann, Nancy B. Davis, Renee McAlister, Kerry Schaffer, Andrew J. Armstrong, Michael R. Harrison, Daniel J. George, W. Kimryn Rathmell, Brian I. Rini, Tian Zhang
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
Kidney neoplasms
Immunotherapy
Tumor biomarkers
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/046d21ea12ea41aeaea7c6d824b8b8a6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/046d21ea12ea41aeaea7c6d824b8b8a6

Ejemplares similares